House QALY Bill Overreach Threatens Medicare Price Negotiation Program, Democrats Warn
Executive Summary
Concern about disrupting the implementation of the negotiation program could presage a tough road for the legislation in the Democrat-controlled Senate.
You may also be interested in...
QALY Bill Clears House But Its Vague Ban Against ‘Similar Measures’ Unlikely To Succeed In Senate
The legislation is a ‘Trojan horse’ designed to undermine the Biden Administration’s policies on cutting drug prices, a leading Democrat claims.
Whiteboarding Ideas From Novartis, Novo To Address India’s Elephants In The Room, ‘On Streets’
Senior VPs from Novartis and Novo Nordisk offered suggestions ranging from protecting IP and fixing the perception of “elephants roaming the streets,” to “fit for purpose” global development plans to improve the research landscape in India, during a recent webinar, which also saw academia weighing in on various issues.
Novo Nordisk’s Cardiovascular Claim For Wegovy Will Enable Medicare Coverage, CBO Assumes
Medicare has not issued a policy allowing for Part D coverage of obesity drugs with additional health claims like Wegovy’s. But expectations are growing that it will.